CD80 and cancer: Immunotherapy using antibodies to target immune checkpoints (immune checkpoint inhibitors, ICIs), including the PD-1/PD-L1 and CTLA-4/CD80 pathways, has shown promising anti-cancer effects in a variety of cancers (8–10).